Sessioni Comunicazioni Orali
PHARMACOGENETICS, PHARMACOGENOMICS AND GENE THERAPY
28/10/2017 / 9.00 - 11.00
| 113 | THE PREDICTIVE VALUE OF ABCB1, ABCG2, CYP3A4/5, AND CYP2D6 POLYMORPHISMS FOR RISPERIDONE AND ARIPIPRAZOLE PLASMA CONCENTRATIONS AND THE OCCURRENCE OF ADVERSE DRUG REACTIONS 1)Bernardi FF. 2)Vitale A. 3)Sessa M. 4)Mascolo A. 5)Scavone C. 6)Maccariello A. 7)Rafaniello C. 8)Rossi F. 9)Capuano A. |
| 114 | CLOPIDOGREL PHARMACOGENETICS: A VALID METHOD TO ASSURE EFFECTIVENESS AND APPROPRIATENESS OF THE ANTIPLATELET THERAPY 1)Conti V.. 2)Manzo V.. 3)Sellitto C.. 4)Iannaccone T.. 5)Costantino M.. 6)Corbi G.. 7)Malangone P.. 8)Tarallo S.. 9)Iannello F.. 10)Nicolella G.. 11)Accarino G.. 12)Filippelli A.. |
| 115 | COMPARISON OF FOUR DIFFERENT ASSAY METHODS FOR UGT1A1*28 GENOTYPING 1)Costanza F.. 2)Mancini I.. 3)Salvianti F.. 4)Gelmini S.. 5)Tassi R.. 6)Mazzei T.. 7)Nobili S.. 8)Mini E.. 9)Pazzagli M.. 10)Pinzani P.. 11)Simi L.. |
| 116 | PHARMACOGENETICS OF SOFOSBUVIR , A NEW ANTI-HCV DRUG: A PRELIMINARY STUDY. 1)Cusato J. 2)De nicolo' A. 3)Boglione L. 4)Ariaudo A. 5)Favata F. 6)Mornese pinna S. 7)Carcieri C. 8)Di perri G. 9)D'avolio A. |
| 117 | TACKLE ATHEROSCLEROSIS VIA GENOME EDITING: CRISPR MEETS ApoA-I MILANO 1)Pizzino G. 2)Mannino F. 3)Irrera N. 4)Pallio G. 5)Galfo F. 6)Mecchio A. 7)Minutoli L. 8)Squadrito F. 9)Altavilla D. 10)Bitto A. |
| 118 | PREPARE (PRE-EMPTIVE PHARMACOGENOMIC TESTING FOR PREVENTING ADVERSE DRUG REACTIONS), A PHARMACOGENOMIC RANDOMIZED CLINICAL TRIAL WITHIN THE U-PGX H2020 PROGRAM, TO DRIVE PHARMACOGENOMICS INTO CLINICAL PRACTICE IN 7 EUROPEAN CLINICAL ENVIRONMENTS, TO IMPROVE PATIENTS SAFETY AND QUALITY OF LIFE- THE ITALIAN EXPERIENCE 1)Bignucolo A.. 2)Roncato R.. 3)Di raimo T.. 4)De mattia E.. 5)D'andrea M.. 6)Giordano G.. 7)Foltran L.. 8)Berretta M.. 9)De paoli A.. 10)Guardascione M.. 11)Lo re G.. 12)Buonadonna A.. 13)Saracchini S.. 14)Favaretto A.. 15)Sandri P.. 16)Toffoli G.. |
| 119 | A TRANSCRIPTOMIC PROFILE PREDICTS CLINICAL OUTCOME IN STAGE III COLORECTAL CANCER PATIENTS TREATED WITH ADJUVANT CHEMOTHERAPY 1)Nobili S. 2)D'aurizio R. 3)Perrone G. 4)Magi A. 5)Lapucci A. 6)Tassi R. 7)Napoli C. 8)Picariello L. 9)Landini I. 10)Brugia M. 11)Mazzei T. 12)Tonelli F. 13)Mini E. |
| 120 | Identification and validation of ADME polymorphic variants correlated to taxane neurotoxicity and survival in breast cancer patients by DMET microarray platform 1)Arbitrio M.. 2)Viscomi C.. 3)Di martino MT. 4)Botta C.. 5)Galeano T.. 6)Staropoli N.. 7)Iuliano E.. 8)Scionti F.. 9)Altomare E.. 10)Iannone M.. 11)Vecchio I.. 12)Strongoli MC. 13)Agapito G.. 14)Cannataro M.. 15)Tassone P.. 16)Tagliaferri P.. |
| 121 | Immunogenetics of prostate cancer: first clinical insights 1)Dreussi E. 2)Zanusso C. 3)Gagno S. 4)De mattia E. 5)Romanato L. 6)Sartor F. 7)Bortolus R. 8)Romualdi C. 9)Quartuccio L. 10)Cecchin E. 11)Toffoli G. |